Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
PRFX Stock Summary
Top 10 Correlated ETFs
PRFX
In the News
PainReform to Present at the Microcap Conference in Atlantic City
TEL AVIV, Israel, Jan. 22, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. ( Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that management will be participating at The Microcap Conference which is being held on January 30 - February 1, 2024 at Caesars Atlantic City Hotel & Casino in Atlantic City, NJ.
PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City
TEL AVIV, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform will be attending the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.
Why Is PainReform (PRFX) Stock Up 38% Today?
PainReform (NASDAQ: PRFX ) stock is rallying on Thursday after the pharmaceutical company regained compliance with Nasdaq listing requirements. According to the company's press release, it was sent notice of it regaining compliance on July 18.
PRFX Stock: The $2.7 Million Reason PainReform Is Up 100% Today
In the world of biotech stocks, one company that's generating big buzz today is PainReform (NASDAQ: PRFX ). The Israeli clinical-stage pharmaceutical company has seen its stock price absolutely skyrocket.
Why Is PainReform (PRFX) Stock Down 40% Today?
PainReform (NASDAQ: PRFX ) stock is falling on Wednesday after the company announced a concurrent registered direct offering and private placement. The registered direct offering has PainReform agreeing to sell 301,230 shares of PRFX stock at a price of $9 per share.
PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st
TEL AVIV, Israel, June 15, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, will be presenting at the Maxim Group Virtual Healthcare Conference, hosted by M-Vest, which is being held June 20-22, 2023.
Why Is PainReform (PRFX) Stock Up 48% Today?
PainReform (NASDAQ: PRFX ) stock is rocketing higher on Wednesday following an update on its delisting ordeal. A press release confirms that the company has received a letter from The Nasdaq Stock Market.
PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference
TEL AVIV, Israel, Sept. 01, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference which is being held September 12th - 14th, 2022. The event will include virtual participation as well as in-person participation at the Lotte New York Palace Hotel in New York City.
PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th
TEL AVIV, Israel, March 21, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced it will present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.
PRFX Stock: 8 Things to Know About PainReform as Shares Trend on Unusually Heavy Volume Today
PainReform (PRFX) stock is on the move Monday with heavy trading despite a lack of news coming from the medical device company. The post PRFX Stock: 8 Things to Know About PainReform as Shares Trend on Unusually Heavy Volume Today appeared first on InvestorPlace.
PRFX Financial details
PRFX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0.08 | 0 | |
Net income per share | -3.14 | -12.49 | -7.38 | -8.25 | -7.14 | |
Operating cash flow per share | -1.05 | -7.88 | -6.68 | -6.06 | -5.1 | |
Free cash flow per share | -1.05 | -7.91 | -6.73 | -6.06 | -5.11 | |
Cash per share | 1.62 | 48.33 | 16.85 | 9.55 | 6.14 | |
Book value per share | -9.7 | 51.23 | 18.43 | 10.34 | 5.53 | |
Tangible book value per share | -9.7 | 51.23 | 18.43 | 10.34 | 5.53 | |
Share holders equity per share | -9.7 | 51.23 | 18.43 | 10.34 | 5.53 | |
Interest debt per share | 11.58 | 3.04 | 0.01 | 0.06 | 0.36 | |
Market cap | 3.91M | 1.45M | 1.31M | 440.31K | 3.6M | |
Enterprise value | 9.14M | -14.23M | -15.23M | -3.66M | -4.35M | |
P/E ratio | -2.15 | -0.36 | -0.18 | -0.05 | -0.39 | |
Price to sales ratio | 0 | 0 | 0 | 5.12 | 0 | |
POCF ratio | -6.41 | -0.57 | -0.2 | -0.07 | -0.54 | |
PFCF ratio | -6.41 | -0.56 | -0.2 | -0.07 | -0.54 | |
P/B Ratio | -0.69 | 0.09 | 0.07 | 0.04 | 0.5 | |
PTB ratio | -0.69 | 0.09 | 0.07 | 0.04 | 0.5 | |
EV to sales | 0 | 0 | 0 | -42.51 | 0 | |
Enterprise value over EBITDA | -12.4 | 8.18 | 2.11 | 0.42 | 0.45 | |
EV to operating cash flow | -15.01 | 5.56 | 2.32 | 0.57 | 0.65 | |
EV to free cash flow | -15.01 | 5.54 | 2.31 | 0.57 | 0.65 | |
Earnings yield | -0.47 | -2.8 | -5.55 | -19.97 | -2.6 | |
Free cash flow yield | -0.16 | -1.77 | -5.06 | -14.68 | -1.86 | |
Debt to equity | -1.1 | 0 | 0 | 0 | 0.01 | |
Debt to assets | 5.3 | 0 | 0 | 0 | 0.01 | |
Net debt to EBITDA | -7.1 | 9.01 | 2.29 | 0.47 | 0.83 | |
Current ratio | 0.15 | 18.51 | 25.13 | 11.55 | 4.07 | |
Interest coverage | -1.27 | -1.69 | -720.8 | -145.39 | -24.96 | |
Income quality | 0.48 | 0.63 | 0.9 | 0.73 | 0.71 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 51.71 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 51.42 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.01 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | -0.07 | 0 | |
Capex to depreciation | 0 | -0.01 | -7.14 | -0.4 | -0.6 | |
Stock based compensation to revenue | 0 | 0 | 0 | 16.15 | 0 | |
Graham number | 26.18 | 120.01 | 55.33 | 43.8 | 29.8 | |
ROIC | -1.78 | -0.11 | -0.4 | -0.81 | -1.3 | |
Return on tangible assets | -1.56 | -0.23 | -0.38 | -0.71 | -0.94 | |
Graham Net | -10.05 | 47.95 | 17.15 | 12.03 | 4.11 | |
Working capital | -5.37M | 16.83M | 18.26M | 11.22M | 7.39M | |
Tangible asset value | -5.62M | 16.62M | 18.08M | 11.02M | 7.24M | |
Net current asset value | -5.81M | 16.61M | 18.03M | 10.98M | 7.11M | |
Invested capital | -1.1 | 0 | 0 | 0 | 0.01 | |
Average receivables | 25K | 37.5K | 135.5K | 136.5K | 50K | |
Average payables | 1000 | 360K | 428K | 172.5K | 215K | |
Average inventory | 3K | 1.02M | 2.14M | 5.03M | 3.91M | |
Days sales outstanding | 0 | 0 | 0 | 233.43 | 0 | |
Days payables outstanding | 0 | 0 | 7.09K | 5.09K | 5.38K | |
Days of inventory on hand | 2.19K | 0 | 116.54K | 190.36K | 0 | |
Receivables turnover | 0 | 0 | 0 | 1.56 | 0 | |
Payables turnover | 0 | 0 | 0.05 | 0.07 | 0.07 | |
Inventory turnover | 0.17 | 0 | 0 | 0 | 0 | |
ROE | 0.32 | -0.24 | -0.4 | -0.8 | -1.29 | |
Capex per share | 0 | -0.03 | -0.05 | -0.01 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.08 | 0 | 0 | 0 | 0 | |
Net income per share | -2.96 | -2.05 | -2.03 | 0.03 | -3.49 | |
Operating cash flow per share | -2.7 | -1.82 | -1.87 | -0.96 | -1.06 | |
Free cash flow per share | -2.7 | -1.82 | -1.87 | -0.97 | -1.06 | |
Cash per share | 9.57 | 7.59 | 5.74 | 7.02 | 5.74 | |
Book value per share | 10.36 | 8.29 | 6.5 | 7.07 | 5.17 | |
Tangible book value per share | 10.36 | 8.29 | 6.5 | 7.07 | 5.17 | |
Share holders equity per share | 10.36 | 8.29 | 6.5 | 7.07 | 5.17 | |
Interest debt per share | -0.09 | -0.1 | 0 | 0.08 | 0.06 | |
Market cap | 439.19K | 739.76K | 588.59K | 4.25M | 3.85M | |
Enterprise value | -3.66M | -7.4M | -4.55M | -3.21M | -4.1M | |
P/E ratio | -0.03 | -0.08 | -0.07 | 29.52 | -0.2 | |
Price to sales ratio | 5.11 | 0 | 0 | 0 | 0 | |
POCF ratio | -0.15 | -0.38 | -0.29 | -3.63 | -2.6 | |
PFCF ratio | -0.15 | -0.38 | -0.29 | -3.6 | -2.6 | |
P/B Ratio | 0.04 | 0.08 | 0.08 | 0.49 | 0.53 | |
PTB ratio | 0.04 | 0.08 | 0.08 | 0.49 | 0.53 | |
EV to sales | -42.52 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 1.15 | 3.06 | 2.03 | 1.07 | 1.15 | |
EV to operating cash flow | 1.28 | 3.79 | 2.27 | 2.74 | 2.77 | |
EV to free cash flow | 1.27 | 3.79 | 2.27 | 2.72 | 2.77 | |
Earnings yield | -7.16 | -2.97 | -3.71 | 0.01 | -1.27 | |
Free cash flow yield | -6.54 | -2.64 | -3.4 | -0.28 | -0.38 | |
Debt to equity | 0 | 0 | 0 | 0.01 | 0.01 | |
Debt to assets | 0 | 0 | 0 | 0.01 | 0.01 | |
Net debt to EBITDA | 1.29 | 3.37 | 2.29 | 2.49 | 2.23 | |
Current ratio | 11.55 | 8.1 | 7.55 | 9.81 | 4.07 | |
Interest coverage | 32.89 | 22.37 | -563 | -270.4 | -1.19K | |
Income quality | 0.91 | 0.85 | 0.92 | -32.56 | 0.3 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 15.2 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 22.66 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0.01 | 0 | |
Capex to revenue | -0.07 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -1 | 0 | 0 | -2.67 | -0.16 | |
Stock based compensation to revenue | 8.56 | 0 | 0 | 0 | 0 | |
Graham number | 26.26 | 19.56 | 17.25 | 2.17 | 20.16 | |
ROIC | -0.29 | -0.26 | -0.31 | -6.06 | -0.49 | |
Return on tangible assets | -0.26 | -0.21 | -0.26 | 0 | -0.49 | |
Graham Net | 12.06 | 6.17 | 4.49 | 5.18 | 3.84 | |
Working capital | 11.22M | 9.1M | 7.18M | 9.65M | 7.39M | |
Tangible asset value | 11.02M | 8.89M | 6.97M | 8.64M | 7.24M | |
Net current asset value | 10.98M | 8.85M | 6.94M | 8.5M | 7.11M | |
Invested capital | 0 | 0 | 0 | 0.01 | 0.01 | |
Average receivables | 27.5K | 27.5K | 0 | 0 | 22.5K | |
Average payables | 297K | 261K | 191.5K | 142K | 217.5K | |
Average inventory | 3.91M | 3.91M | 0 | 0 | 0 | |
Days sales outstanding | 57.56 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 3.14K | 14.09K | 1.58K | 6.42K | 3.32K | |
Days of inventory on hand | 117.35K | 0 | 0 | 0 | 0 | |
Receivables turnover | 1.56 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.03 | 0.01 | 0.06 | 0.01 | 0.03 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.29 | -0.25 | -0.31 | 0 | -0.68 | |
Capex per share | -0.01 | 0 | 0 | -0.01 | 0 |
PRFX Frequently Asked Questions
What is PainReform Ltd. stock symbol ?
PainReform Ltd. is a IL stock and trading under the symbol PRFX
What is PainReform Ltd. stock quote today ?
PainReform Ltd. stock price is $1.78 today.
Is PainReform Ltd. stock public?
Yes, PainReform Ltd. is a publicly traded company.